Most people with atypical hemolytic uremic syndrome (aHUS) who are stable on Soliris (eculizumab) can stop treatment after at least six months without having a relapse, provided that they’re carefully monitored, a recent study reported. Scientists expect that this could prevent treatment-related complications and burden for patients, while…
News
Atypical hemolytic uremic syndrome (aHUS) can occur as a rare complication of surgery involving the urinary tract, according to a report from Italy detailing the case of a woman in her 40s who developed the condition after undergoing a procedure to remove kidney stones. The patient, who had a…
A 38-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) after giving birth via cesarean section successfully recovered following treatment with Soliris (eculizumab), a case report from China shows. Genetic testing revealed the presence of a mutation in the CFH gene, which likely contributed to her condition.
Short-term use of Soliris (eculizumab) in India — where the drug was approved just this year for treating two rare diseases — was effective for five children with atypical hemolytic uremic syndrome (aHUS), according to a new report. While the antibody therapy has been approved as an aHUS…
Adults with atypical hemolytic uremic syndrome (aHUS) who start Soliris (eculizumab) within seven days after their symptoms start see the best outcomes, a small real-world study in Western China suggests. The patients showed significantly improved blood and kidney function, and a reduced need for dialysis, while most given…
Atypical hemolytic uremic syndrome (aHUS) can occur concurrently with disseminated intravascular coagulation (DIC), a blood disorder marked by similar symptoms, but that has different underlying causes. The case of a boy with both aHUS and DIC was highlighted in the paper, “A Case Report of Atypical…
A 29-year-old woman in the U.S. showed signs of atypical hemolytic uremic syndrome (aHUS) and a C2 gene mutation, but without infection caused by Shiga toxin-producing Escherichia coli (STEC), according to a case report. STEC bacteria are the cause of the typical form of the disease. Genetic testing could…
Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study in Japan. The treatment switch was associated with stable levels of blood and kidney-related disease markers, preventing disease relapse or…
More than half of Chinese children with atypical hemolytic uremic syndrome (aHUS) have self-reactive antibodies targeting complement factor H, a protein that regulates the activity of the immune complement cascade, a study showed. In turn, predisposing genetic mutations were detected in only 20% of the more than 100 children with aHUS…
Atypical hemolytic uremic syndrome (aHUS) may be triggered by acute inflammation of the pancreas, or pancreatitis, a team of researchers from India highlighted in a report describing the case of a 36-year-old man with both conditions. The man sought medical attention due to abdominal pain and was found to…
Recent Posts
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse
- For women like me, hair loss can be particularly devastating
- aHUS drugs restore kidney function in 60% of patients in Romania
- aHUS has changed my life in drastic and unexpected ways
- Rare lupus nephritis–aHUS case improves after Soliris treatment
- How my young children had to adapt to having a sick parent